HomeEVGN • NASDAQ
add
Evogene Ltd
Previous close
$1.05
Day range
$1.04 - $1.08
Year range
$0.99 - $8.90
Market cap
5.63M USD
Avg Volume
20.56K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
MarketWatch
14 hours ago
S&P 500 tallies its first ‘death cross’ in 3 years. Here’s what happens next.
0.79%
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.61M | 178.72% |
Operating expense | 5.92M | -24.14% |
Net income | 427.00K | 106.47% |
Net profit margin | 26.51 | 102.32% |
Earnings per share | 0.06 | 104.62% |
EBITDA | -4.47M | 35.76% |
Effective tax rate | 350.00% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 15.31M | -50.71% |
Total assets | 39.86M | -21.99% |
Total liabilities | 25.03M | 11.64% |
Total equity | 14.84M | — |
Shares outstanding | 6.51M | — |
Price to book | -4.77 | — |
Return on assets | -31.68% | — |
Return on capital | -83.71% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 427.00K | 106.47% |
Cash from operations | -5.21M | 12.12% |
Cash from investing | 8.76M | 1,594.54% |
Cash from financing | 440.00K | 399.32% |
Net change in cash | 3.98M | 160.74% |
Free cash flow | -9.20M | -148.92% |
About
Evogene is a computational biology company based in Israel, specializing in predictive biology platforms that leverage artificial intelligence and machine learning for life-science product development. Evogene's platforms focus on designing novel microbes, small molecules, and genetic elements for use in pharmaceuticals, agriculture, and related industries. In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
Founded
2002
Website
Employees
117
